Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).
about
Apolipoprotein A-1 predicts coronary heart disease only at low concentrations of high-density lipoprotein cholesterol: an epidemiological study of Japanese-AmericansSerum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysisThe relationship between Lp(a) and CVD outcomes: a systematic reviewA randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trialNovel serologic markers of cardiovascular riskMultiethnic meta-analysis of genome-wide association studies in >100 000 subjects identifies 23 fibrinogen-associated Loci but no strong evidence of a causal association between circulating fibrinogen and cardiovascular diseaseEvaluation of methods for the measurement of low-density lipoprotein cholesterol.Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biologyThe Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases.Lipoprotein (a) and strokeLipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy.ENDOTHELIN-1 SYTEM ACTIVITY IN ADULTS WITH BORDERLINE HIGH LDL-CHOLESTEROL.The role of risk factors in the development of atherosclerosis.Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events.Enigmatic role of lipoprotein(a) in cardiovascular disease.No evidence for genome-wide interactions on plasma fibrinogen by smoking, alcohol consumption and body mass index: results from meta-analyses of 80,607 subjects.Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular diseaseFibrinogen: biochemistry, epidemiology and determinants.Lipoprotein(a): an elusive cardiovascular risk factorHigh prevalence of raised lipoprotein(a) in patients with refractory anginaRelationship between Lipoprotein(a) and Thyroid Hormones in Hypothyroid Patients.The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory anginaIdentification of two functionally distinct lysine-binding sites in kringle 37 and in kringles 32-36 of human apolipoprotein(a).Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).Functional analysis of the chimpanzee and human apo(a) promoter sequences: identification of sequence variations responsible for elevated transcriptional activity in chimpanzee.The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies.Lipoprotein(a) in health and disease.HyperLp(a)lipoproteinaemia: unmet need of diagnosis and treatment?Lipoprotein(a) as a risk factor for maternal cardiovascular disease mortality in kindreds with familial combined hyperlipidemia or familial hypertriglyceridemia.The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura).Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging.Associations of plasma fibrinogen assays, C-reactive protein and interleukin-6 with previous myocardial infarction.Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function.Direct comparisons of three alternative plasma fibrinogen assays with the von Clauss assay in prediction of cardiovascular disease and all-causes mortality: the Scottish Heart Health Extended Cohort.Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women.Apolipoproteins A-I, A-II and B, lipoprotein(a) and the risk of ischaemic heart disease: the Caerphilly study.Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial.[Lipoprotein(a): influence on cardiovascular manifestation].
P2860
Q23911481-8C26446D-2828-46CC-8C53-67F6972F7C5CQ24805426-6611845D-F902-4242-825B-4391E43959C5Q26749317-BA31DE03-60CC-4D57-B016-5E4691B755F2Q28210362-B239657D-0BD5-4DA5-B377-4E7F78E96C74Q28218040-0222CA68-E567-45A0-8BDC-5C04A73869BCQ28661433-FD49E474-C98B-439F-B152-F9CACC3CA1CAQ29547378-29CABFB6-BB65-4EFE-8D7A-E2E0C65690E7Q30242031-552C86A9-33EF-4E14-8F10-9D9BB682B8B5Q31129827-80A90B56-5108-4BF4-B2D2-5D0801301986Q34015050-9F2204DF-C118-4D41-997E-87A2F4BC43FFQ34116379-F7349352-A639-4AE1-860C-1D38E4264030Q34245580-98BE56BF-216C-4E9B-89DD-2389AD8E6F40Q34447107-0B8468D2-5835-4FFF-8EED-89E400A7EFCBQ34658104-A59A1091-124D-4EFD-B0F6-2750A7AFEC24Q34786504-66C433AD-BC08-4F80-A8E5-7ADA34335A06Q34796836-799C28E2-C78C-42E8-A16A-A40FAFA6C5B2Q34820339-E24E8D0A-7ECC-4F99-859E-69D5EC12EEAAQ35182640-9B8999C6-DF6C-46A9-9491-44967EEF79D0Q35538771-5F8CF9F9-D7E0-4C57-9943-B9964A8FD4C2Q35746190-632AF446-4018-4EB4-A1F0-31DA75D201D1Q36187468-501AAD35-D364-4F60-B864-FBB753CEA64DQ37679079-5D6A899C-D993-4784-AE8E-B26CD3B3B471Q38233052-955AA54E-4D53-4691-9232-1BF9C909CCD7Q38297505-481332CF-92D9-4C4E-8BFD-34726C3C22A0Q39148923-D4815C1B-FFEC-4512-9B77-DEECD3FDC147Q40812882-018831D0-DBD9-4B8E-B45B-15F607AEBE84Q40866572-3FD9210E-6ABB-465A-938B-0C7583D813ECQ41300659-9908A7D1-4948-4C5D-A204-9C62831CB752Q42396853-B0424483-A972-4224-8C44-68D2E51BED86Q43762325-79FBBC8E-99CD-4C98-9132-07CD49790572Q44884393-024202E4-C234-41EA-B8CF-5E2EA61A804EQ46044477-8BF2B7D9-F6F0-49DD-8D21-250864710030Q47373856-0FA42AF8-0500-41DA-A0A1-BDEB4F2B3486Q47729039-7269094B-7BED-41D9-BC66-C09D1417D013Q50967844-30F9E659-6BAD-401B-B41D-73DFA2203046Q51544036-265B6744-D522-4DE7-9D4C-903C2BB30332Q51552231-33CBAC3B-5AB6-4131-BBB1-55E774EBE95EQ51556296-28411933-D76B-4CED-938B-DB2DA3D1C181Q53325503-A5CC98D9-C2DF-4899-A2C8-F6E31513A381Q53614132-5AFF018A-E72A-4C28-95C0-83B6B304BE26
P2860
Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@en
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@nl
type
label
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@en
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@nl
prefLabel
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@en
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@nl
P2093
P2860
P1476
Lipoprotein Lp(a) as predictor ...... and Prevalence Study (GRIPS).
@en
P2093
P2860
P304
P356
10.1111/J.1365-2362.1994.TB02373.X
P577
1994-07-01T00:00:00Z